



VisionQuest Biomedical, LLC

Company Overview: VisionQuest Biomedical, LLC is a medical technology company with a patent pending for screening retinal images for diseases such as age-related macular degeneration, diabetic retinopathy, and other common retinal diseases. VisionQuest was founded in 2007 by Peter Soliz, Ph.D. who has raised \$6 million dollars in R&D funding from the National Institutes of Health.

Problem: Less than 60 percent of the more than 23 million diabetics in the U.S. receive eye examinations due to cost and lack of trained medical resources. Manual eye screening of the 130 million other persons at-risk for age-related eye diseases is economically prohibitive. Physicians' re-imburement does not cover the associated costs.

Solution: VisionQuest's product, EYESTAR™, is the first screening system in the market that makes it possible to effectively, efficiently, and economically combine the power of computer-assisted screening with the irreplaceable expertise of eyecare professionals. EYESTAR overcomes the main obstacles that currently prevent mass screening at the point of care, namely ease of use, performance, speed, cost and effectiveness.

Business Model: Initial market entry will be at the offices of family care physicians, optometrists, and other primary healthcare providers where at-risk individuals, such as diabetics, frequently first see a doctor regarding diabetes or other eye-related issues or get fitted for glasses.

Market Opportunity: EYESTAR will enable family care physicians to offer improved healthcare to their patients, while providing them with a new source of revenues. It will also offer to the health insurance companies an economical and cost effective means for health management.

Competitive Advantage: Patent-pending technology. Unique algorithm analyzes images for all eye diseases. As yet, commercial automated screening is unavailable.

Management Team: Peter Soliz, PhD, CEO and president, responsible for the development of the automated retina screening software. Dr. Wendall Bauman, MD., retinal specialist who has been working with Dr. Soliz for over eight years on projects related to retinal diseases. Dr. Bauman will be the medical director for the future Eye Disease Screening Center.

Funding Request: VisionQuest Biomedical seeks \$5 million over two rounds of funding to acquire FDA clearance/approval, productization, and for equipment and Eye Disease Screening Center startup costs.

Round 1:

\$.75 million for FDA clinical trials

\$.75 million to complete software verification and validation

\$2 million to complete software productization

Round 2:

\$1.5 million for equipment and startup costs



PETER SOLIZ

Year Founded: 2007
Employees: 8

*VisionQuest
Biomedical, LLC
2501 Yale Blvd SE
Suite 301
Albuquerque, NM 87106
psoliz@visionquest-bio.
com
505-508-1994*

In Attendance:
Peter Soliz, Ph.D.

Revenue Forecast:

2011:	\$ 1.4M
2012:	\$ 4.4M
2013:	\$ 11.9M
2014:	\$ 25.1M
2015:	\$ 46M